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Abstract:   Children’s exposure to secondhand smoke (SHSe) can lead to significant health 
consequences, including respiratory illness, asthma, and impaired pulmonary function. For 
children diagnosed with a chronic illness, such as Sickle Cell Disease, SHSe can compound an 
already difficult problem. Among children with SCD, SHSe causes displacement of oxygen from 
hemoglobin, injury to vascular endothelium, and abnormal activation of platelets, each of which 
increases the prevalence of sickle cell crises. Sickle cell crises are painful episodes that occur 
when sickle-shaped red blood cells block blood vessels from providing oxygen to the bodies 
organs and tissues, resulting in severe pain. To date, no prevalence data or objective measurement 
of SHSe exists to document rates of SHSe in children diagnosed with SCD. Therefore, the overall 
aim of the current study is to determine to what extent children diagnosed with SCD are exposed 
to SHSe. We  recruited two groups of families, those who smoke and have children exposed to 
SHSe versus nonexposed children. Each child from both the exposed and nonexposed group  
provided a sample of saliva to examine cotinine levels (i.e., object measurement of SHSe). In 
addition, a medical chart review will provide a preliminary examination of any differences in 
health care utilization for each group. Thirty-one youth and their primary caregiver were recruited 
to participate in the present study. Due to equipment failure, four cotinine samples were unable to 
be processed. The remaining 27 cotinine samples indicated that regardless of parent-reported 
SHSe, 24 of the 27 children were exposed to SHS. Because 24 of the 27 children were exposed to 
some level of SHSe, no inferential statistics were utilized. Descriptive statistics regarding tobacco 
use, perceived harm, and frequency of sickle cell crises, emergency department utilizations, and 
acute chest syndromes are reported. The findings in this dissertation, particularly those 
identifying the frequency of individuals exposed to SHSe, indicate a need to assess for SHSe in 
this population in the future. Future research should aim to better understand and, ultimately, 
reduce the factors that might increase exposure to SHSe in youth with SCD, and therefore 
decrease potential harm associated with SHSe. 
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CHAPTER I 
 
RESEARCH STRATIGY 
 
Specific Aims 
Children’s exposure to secondhand smoke (SHSe) can lead to significant health 
consequences, including respiratory illness, asthma, and impaired pulmonary function 
(Chen, Burton, Baker, Mastey, & Mannino, 2010; Health & Services, 2006; Jinot & 
Bayard, 1992; Marano, Schober, Brody, & Zhang, 2009; Needs, 2009; Pickett, Schober, 
Brody, Curtin, & Giovino, 2006; Schwab, McDermott, & Spengler, 1992). For children 
diagnosed with a chronic illness, such as Sickle Cell Disease, SHSe can compound an 
already difficult problem. 
Children with SCD are an underserved and understudied population with high 
risk for morbidity and mortality (CDC, 2012). Literature has shown that children with 
SCD incurred medical expenditures that were $9369 and $13,469 higher than those of 
children without SCD enrolled in Medicaid and private insurance, respectively 
(Amendah, Mvundura, Kavanagh, Sprinz, & Grosse, 2010), with expenditures of children 
with SCD being 6 and 11 times higher than children without SCD (Amendah et al, 2010). 
In 2005, SCD-attributable medical expenditures in children were conservatively and 
approximately estimated at $335 million (Amendah et al., 2010). Among children with 
SCD, SHSe causes displacement of oxygen from hemoglobin (Davis, Shelton, & 
Watanabe, 1989; West et al., 2003), injury to vascular endothelium, and abnormal 
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activation of platelets (Celermajer et al., 1996; Davis et al., 1989), each of which 
increases the prevalence of sickle cell crises. Sickle cell crises are painful episodes that 
occurs when sickle-shaped red blood cells block blood vessels from providing oxygen to 
the bodies organs and tissues, resulting in severe pain (West et al., 2003).  
 
To date, no prevalence data or objective measurement of SHSe exists to 
document rates of SHSe in children diagnosed with SCD. Establishing prevalence rates 
as well as utilization of health care services and corresponding negative health events is 
an important first step to estimate the scale of the problem. In addition, such research will 
help identify the potential positive individual and public health impact SHSe intervention 
efforts may have. Therefore, the overall aim of the current study was to determine to 
what extent children diagnosed with SCD are exposed to SHSe. We  recruited two groups 
of families, those who smoke and have children exposed to SHSe versus nonexposed 
children. Each child from both the exposed and nonexposed group provided a sample of 
saliva to examine cotinine levels (i.e., object measurement of SHSe). In addition, a 
medical chart review will provide a preliminary examination of any differences in health 
care utilization for each group. To our knowledge, this was the first attempt to determine 
the prevalence rates for SHSe in children with SCD as well as use objective measurement 
of SHSe (Cohen et al., 2013; Glassberg, Wang, Cohen, Richardson, & DeBaun, 2012; 
West et al., 2003).  
Aim 1: To determine the prevalence of secondhand smoke exposure in children 
diagnosed with SCD via self-report, parental report, and objective measurement (i.e., 
salivary cotinine).  
Hypothesis 1.1: Based on previous non-representative studies, it is expected that 
approximately 30 – 40% of sample will be exposed to SHSe, which would be consistent 
with the three studies in the literature to date. 
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Aim 2: To examine the relationship between levels of salivary cotinine and 
utilization of health care services (i.e., Emergency Department Visits) and negative health 
events (e.g., acute chest syndrome, sickle cell crises, pulmonary morbidity).    
Hypothesis 2.1: Youth who have cotinine values > .15 ng/mL, an indication of 
significant SHSe (Salimetrics, 2014; Benowitz, et al., 2009), will demonstrate higher 
levels of utilization of health care services (i.e., Emergency Department Visits) and 
negative health events (e.g., acute chest syndrome, sickle cell crises, pulmonary 
morbidity) compared to those with no exposure.  
 
Significance 
The Risks of Secondhand Smoke Exposure (SHSe) to Children: Secondhand 
tobacco smoke contains at least 250 chemicals that are known to be toxic or carcinogenic. 
It has been identified as a known human (Class A) carcinogen that presents a serious 
public health risk (Chen, Burton, Baker, Mastey, & Mannino, 2010; Jinot & Bayard, 
1992). Children experience the highest amount of SHSe of any age group, with more than 
50% of children in the U.S. exposed to secondhand smoke (Control & Prevention, 2010; 
Health & Services, 2006). Children between the ages of 3 and 11-years-old have the 
highest levels of SHSe, likely because they spend a majority of their time in close 
proximity to a caregiver who smokes (Gergen, Fowler, Maurer, Davis, & Overpeck, 1998; 
Health & Services, 2006; Pirkle, Bernert, Caudill, Sosnoff, & Pechacek, 2006; Schwab, 
McDermott, & Spengler, 1992). Nationally, more than 18% of youth ages 0 to 17-year-
olds live with a smoker (approximately 12,480 children) and surprisingly, 20% 
(approximately 3,463) of children ages 0 – 17 who have a special health care need live 
with a smoker (Needs, 2009). In Oklahoma, it is estimated that  35% of healthy children 
live with a smoker, and 42% of children who have been identified as having a special 
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health care need live with a smoker (Needs, 2009). Furthermore, despite smoking bans in 
public spaces, children living with smokers have not experienced any reduction in their 
exposure as evidenced by mean serum cotinine levels (Asplund, 2003; Marano, Schober, 
Brody, & Zhang, 2009; Pickett, Schober, Brody, Curtin, & Giovino, 2006; Pirkle et al., 
2006). Although SHSe in the home is often problematic, SHSe in the car is also a 
substantial concern (Park et al., 1997). Despite the use of forced ventilation or open car 
windows, children are still exposed to dangerous levels of SHSe (Semple et al., 2012).  
SHSe decreases lung growth and increases the incidence of sudden infant death, 
respiratory illness, middle-ear disease, wheezing, and asthma (Health & Services, 2006; 
Mannino, Moorman, Kingsley, Rose, & Repace, 2001). For young children, it is 
estimated that 150,000 to 300,000 new cases of pneumonia and bronchitis and 7,500 to 
15,000 hospitalizations occur each year due directly to SHSe (Jinot & Bayard, 1992). 
SHSe is also associated with lower cognitive test scores and increased school absence 
(Mannino et al., 2001; Yolton, Dietrich, Auinger, Lanphear, & Hornung, 2005). 
Identifying and assessing the extent to which children with SCD are exposed to SHSe 
is critical to decreasing negative health and functional impairment consequences.  
 
The Risks of Secondhand Smoke Exposure (SHSe) to Medically At-Risk Children:  
Although all children, whether medically at-risk or not, should be protected from 
SHSe, there are a number of issues that distinguish clinical and research efforts with at-
risk populations from those children who are not at risk because of their medical status. 
The life threatening nature of some childhood diseases, such as Sickle Cell Disease 
(SCD), and their often invasive and intensive treatment regimens present a demanding 
challenge for parents of medically compromised children. However, limited data are 
available regarding exposure rates among medically at-risk children (Needs, 2009). More 
disturbing, children with chronic medical conditions may be physically unable to remove 
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themselves from the smoke to avoid exposure, and thus more likely to spend a significant 
proportion of their time indoors with their parents or caregiver due to disease restrictions, 
and thereby increase their risk for SHSe.  
To date, only three studies have examined SHSe exposure in SCD (Cohen et al., 
2013; Glassberg, Wang, Cohen, Richardson, & DeBaun, 2012; West et al., 2003). West 
et al. (2003) found that 42% of children with SCD were exposed to SHS and estimated 
that SHSe increased the risk of a sickle cell crisis by as much as 90%. Patients were 
considered exposed if either their parent or primary caretaker identified anyone living in 
the home that smoked any tobacco products in the preceding two years (West et al., 
2003). The second study examined potential risk factors associated with increased 
emergency department (ED) use in children with SCD (Glassberg et al., 2012). Of the 
985 children recruited from the United States, Canada, England, and France, study results 
found that SHSe in the home was associated with 73% more ED visits for acute chest 
syndrome (Glassberg et al., 2012).  Lastly, the third study examined pulmonary morbidity 
due to SHSe in children ages 4 to 20-years-old with sickle cell anemia (SCA) from three 
sites, including Missouri, Ohio, and London, England (Cohen et al., 2013). They found 
that roughly 108 of the 245 children (44%) self-reported a history of exposure to SHSe 
and 71 of the 245 (29%) reported current exposure to SHS (Cohen et al., 2013). Children 
who reported current and infant SHSe exposure had poorer forced expiratory flow (i.e., 
the speed of air coming out of the lungs during the middle portion of a forced expiration), 
midexpiratory phase/FVC ratio (i.e., the ratio of speed of air and force of air coming from 
the lungs), increased airway obstruction and increased bronchodilator responsiveness (i.e., 
phenotypic characteristic of chronic obstructive pulmonary disease;(Cohen et al., 2013). 
Importantly, none of these studies involved an objective, physiological measurement of 
smoke exposure, which significantly limits our knowledge of the true extent of exposure to 
smoke. While each of these studies makes a significant contribution to the extant 
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literature examining the impact current and previous SHSe has on children with SCD and 
SCA, our study is the first to objectively measure SHSe in the clinic setting at point of 
care.  
 
Many Smokers are Uninterested, Unwilling, or Unable to Quit:  
Nearly 50% of smokers make a quit attempt each year, but less than 5% remain 
abstinent for 3-12 months after quitting (18 – 23). Although smokers double their chances 
of long-term abstinence with psychological (Lancaster & Stead, 2005; Stead & Lancaster, 
2002) and pharmacological (Hughes, Stead, & Lancaster, 2005; Stead, Perera, Bullen, 
Mant, & Lancaster, 2008) interventions, few smokers utilize these methods (Fiore, 2000). 
As a result, the prevalence of cigarette smoking among adults in the U.S. has only 
slightly decreased between 2005 to 2010 (20.9% vs. 19.3%, respectively) and remains 
disturbingly high (Control & Prevention, 2011). Even among caregivers of children with 
asthma, a medically at-risk population that are generally more motivated to quit smoking, 
the percent who were interested in quitting in the next month was only 27% (Farber et al., 
2008), representing a minority of caregivers. Moreover, approximately 39% of caregivers 
were not interested in quitting smoking at all (Farber et al., 2008). This is a critical 
concern due to the impact SHSe has on children with SCD and the difficulty caregivers 
face when attempting to quit smoking. Understanding the needs of these families to 
reduce SHSe is key to providing appropriate resources to families in need.  
 
Innovation.  
Currently, there is limited research examining biomarkers of SHSe in children 
who are medically at-risk (Tyc et al., 2013). To our knowledge, with regard to SHSe 
biomarkers in SCD, no research has examined the prevalence rates of SHSe in a SCD 
population or the potential dose-response relationship that SHSe may have on health 
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outcomes such as increased ED utilization and other medical complications (e.g., acute 
chest syndrome, sickle cell pain crises) in children diagnosed with SCD.  
Impact on science and clinical practice: Our study is the first to: 1) objectively 
examine the prevalence of SHSe in children with SCD and 2) identify a preliminary dose-
response relationship between SHSe and health outcomes  (e.g., ED visits, sickle pain 
crises, acute chest syndrome). Our study is the foundation in identifying the potential 
need to provide interventions to children exposed to SHSe with SCD.  
 
Approach.   
Overview of Project: We conducted a prevalence survey of all eligible parents 
of children ages 1 month-17-years-old diagnosed with SCD at the University of 
Oklahoma Health Sciences Center, a tertiary care center which provides care to many 
underserved urban and rural populations. Using a battery of questionnaires given to both 
caregivers and children, we assessed health care behaviors and status, health care 
utilization, and smoking history. We  collected cotinine measurements from each child to 
examine smoking status and SHSe exposure. Samples were processed using the 
Salimetrics (College Station, PA) cotinine enzymatic immunoassay kits, per each 
standard kit protocol. Briefly, samples and standards are loaded onto a 96-well plate then 
incubated with cotinine-horseradish peroxidase conjugate and rabbit anti-cotinine 
antibodies at 37C for 1.5 hours with shaking. After incubation, plates are washed then 
treated with tetramethylbenzidine substrate before mixing for 5 minutes then incubating 
in darkness at RT for 25 minutes. The reaction is then stopped with 2M sulfuric acid for 3 
minutes before reading absorbance at 450nm. Data are corrected at 630nm. Results are fit 
using a 4-parameter logistic regression.  
Samples taken at the Oklahoma University Health Sciences Center (OUHSC) 
were processed immediately or stored in sterile cryovials for no longer than 48 hours 
	8	
before being frozen at -20C for short term storage (<30 days) or at -80C for long-term 
(>30 days) storage. A chart review ranging from 2 years prior- to 1 year after the baseline 
collection date was conducted to document previous and future health events.   
Previous research experience 
Alayna Tackett, MS (PI) has been a primary research coordinator for five NIH 
funded clinical research trials (1R01DK092977-01; 1R01CA157460-01A; NCI 
1R21CA164521-01A1; 1R01NR01424801A1; 5R01HD07457902) examining adherence, 
psychosocial interventions, and health disparities in children with solid organ and 
hematopoietic stem cell transplantation, disorders of sexual development, and pediatric 
cancer.  Ms. Tackett also assisted with Dr. Wagener’s (CO-I) R21 (5R21CA16452102) 
examining the efficacy of using a smoke-free, nicotine-containing product (medicinal 
nicotine lozenge vs. dissolvable tobacco lozenge) as a means of reducing the SHSe of 
healthy children among a sample of parents who smoked and were uninterested in 
quitting. Her background and training in research design along with the support of the 
proposed research team provides the knowledge and skill needed to succeed in the 
implementation of this project.  
 
Study Procedures: Recruitment 
We  recruited all eligible participants who have children diagnosed with SCD 
through the Jimmy Everest Cancer (JEC) Center Sickle Cell Clinic at the Oklahoma 
University Health Sciences Center as part of a regularly scheduled clinic visit.  This 
recruitment strategy was consistent with previous studies conducted by Drs. Wagener 
(CO-I) and Mullins (CO-I).  
 
Inclusion/Exclusion Criteria 
In order to be included in the study, participants must: 1) be the primary 
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caregiver (defined as a person who spends the most time with the child and spends a 
minimum of 4 hours per day in the presence of the child); 2) be the parent of a child 
between the ages of 1 month-17-years-old, and diagnosed with a form of SCD. If a 
caregiver had more one or more children between 1 month-17-years-old, we  included the 
youngest as these children are typically exposed to more SHSe (e.g., Priest et al., 2008); 3) 
be fluent in English, 4) the child may not be on palliative care, and 5) have no major 
psychiatric impairment, including psychosis, and/or any current alcohol/drug abuse or 
dependence. Participants’ eligibility was determined in person during Sickle Cell Clinic.  
As part of a regularly scheduled clinic visit, a research assistant approached eligible 
families to ask if they were interested in participating in a research study. If interested, 
the research assistant then completed the informed consent and child assent, administered 
questionnaires, and collected salivary samples.  
 
Participant Compensation 
Each dyad received $30 for participating in the one-time study visit and salivary 
collection.  
 
Measurements 
A trained research assistant  administered all assessments and collections. 
Participants were compensated for completing these assessments.  
 
 
Variables Measured 
Caregivers (N =31; Mothers = 87.1%, Age M = 35.82, SD = 8.21) and their children 
(Male = 52.4%; Age M = 8.55, SD = 5.03) with sickle cell disease were asked to provide 
demographic information, smoking status, and complete biochemical verification of smoking 
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status via exhaled carbon monoxide (CO), using a piCO+ Smokerlyzer (Bedfont Scientific, 
2007), with CO≤10 parts per millions (p.p.m.) indicating confirmed smoking cessation. No 
participants refused CO verification. All children (n= 31), regardless of self-reported tobacco 
exposure, were also asked to provide salivary samples to assess levels of secondhand smoke 
exposure via salivary cotinine analyses and were asked to complete a pulmonary function test 
using forced spirometry. All medical information and history of negative health events were 
obtained via medical chart review. Additional caregiver and child demographics are reported in 
Tables 1 and 2 in Appendix C. 
The institutional review board at the hospital where the study was conducted approved 
this study and it was carried out in compliance with the American Psychological Association 
ethical guidelines. Participants were recruited from as part of a regularly scheduled sickle cell 
comprehensive clinic appointment in the pediatric hematology and oncology clinic in a large 
teaching hospital in the Midwest region of the United States. Eligible caregiver/child dyads were 
first identified through the hematology/oncology clinic patient database and medical eligibility 
was assessed through consultation with the attending physician. Participants’ eligibility was 
determined in person during Sickle Cell Clinic.   
As part of a regularly scheduled clinic visit, a research assistant approached eligible 
families to ask if they are interested in participating in a research study. If interested, the research 
assistant completed the informed consent and when appropriate, child assent, administered 
questionnaires, and collected salivary samples. Eligible caregivers (n = 35) were approached and 
31 were consented (88%) to participate in a private location within the clinic. Reasons for 
declining to participate included too busy (n=2) and not interested (n=2). All caregivers self-
identified as the legal guardian and this was confirmed by the medical team. Participants were 
given modest monetary compensation for study participation ($30).   
 
Child Variables 
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To obtain an estimate of pulmonary functioning, children were asked to complete 5 trials 
of forced spirometry. Each child was given age-appropriate instruction and two practice attempts 
with the spirometry device, after which, each child performed three forced expiratory trials, 
according to the methods recommended by the American Thoracic Society (Medical Section of 
the American Lung Association, 2012). Tests were performed in the standing position. Nose clips 
were not utilized. Spirometric indices were automatically recorded for the "best" test as defined 
by the American Thoracic Society (Medical Section of the American Lung Association, 2012; 
Barreiro, & Perillo, 2004).  
Children also completed exhaled carbon monoxide (eCO) to preliminarily assess for 
SHSe via a commonly used and relative technique. eCO has a half-life range between  2–8 hours. 
Factors such as an individual’s level of physical activity, frequency of tobacco product use, and 
proximity to a wood burning fireplace or stove may impact eCO. eCO has the ability to detect 
smoking between a 6–24 hour period (SRNT Subcommittee on Biochemical Verification, 2002). 
Measurement of eCO is a brief noninvasive procedure that provides immediate results. Following 
the initial purchase of a carbon monoxide (CO) monitor (current models cost around $800-900) 
testing eCO is relatively inexpensive.  
Lastly, children provided salivary cotinine as an additional and more objective measure 
of SHSe. During the inhalation of traditional tobacco cigarettes and use of other nicotine products 
(e.g., electronic cigarettes, nicotine replacement therapy, smokeless tobacco), nicotine is absorbed 
and distributed in the body within seconds (Benowitz, 1996). The detection of exposure to 
tobacco smoke by measurement of cotinine is the preferred method (e.g., Benowitz, 1996; 
Benoqitz, Hukkanen, & Jacob, 2009; Alterman, Fariti, & Niedbala, 2002; Foulds, Bryant, 
Stapleton, Jarvis, & Russell, 1994; Granger, et al., 2007). Salivary and serum cotinine samples 
are highly correlated (Van Vunakis, Tashkin, Rigas, Simmons, Gjika, & Clark, 1989; Bernet, 
McGuffey, Morrison, & Pirkle, 2000) and have an estimated measurement half-life around 17 
hours (Benowitz, 1996). Cotinine levels in biologic fluids can be processed and examined using 
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chromatographic or enzyme immunoassay (EIA) techniques. Despite the ability of 
chromatographic methods achieving higher specificity and sensitivity (Benowitz, 1996), EIA 
cotinine results have been documented to have near precise agreement with chromatographic 
methodology (Alterman, Gariti, & Niedbala, 2002). EIA methodology is also advantageous 
because this technique requires smaller sample volumes than chromatographic methodology 
(Watts, Longone, Knight, & Lewtas, 1990) and can detect cotinine concentrations as low as 0-1 
ng/mL (Salimetrics, 2014). Therefore, because of the age of the individuals providing cotinine 
samples (e.g., children and youth) and the brief nature of the present study (e.g., data collection as 
part of a regular clinic visit), the EIA technique was utilized.  
Regardless of age, all participants were asked to collect salivary samples. If age 
appropriate and willing, whole saliva was collected by tilting the child’s head forward, allowing 
the saliva to pool on the floor of the mouth, and then passing the saliva into a polypropylene vial 
as directed using the Salimetrics salivary collection protocol (Salimetrics, 2014). Samples from 
younger children or children who were unable to pool saliva were collected with the SalivaBio 
Children’s Swab (SCS; Salimertics, 2014). This was conduct by having the child hold the 
SalivaBio Swab under the tongue for 60-90 seconds (Salimetrics, 2014). Samples were frozen in 
an -80 degree lab freezer within five hours of collection for later assay by EIA (Salimetrics, 
2014).  
 
Caregiver Variables 
Smoking history was assessed by asking caregivers a series of questionnaire 
items ranging from number of family members that smoke, interest/confidence in quitting, 
and perception of harm.  Additionally, caregivers  completed questionnaires assessing 
their demographics. eCO levels were also collected.  
 
Rationale for Design 
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Because little to no information is available regarding prevalence of SHSe in 
SCD, all children and caregivers who present to the SCD clinics were recruited. Because 
no data exists for SCD specifically, the available data for caregivers of healthy children 
suggests the existence of large minority of caregivers who smoke (~40%) and studies 
have shown that they have difficulty achieving and maintaining alterations to smoking 
behavior that reduce child SHSe (Priest et al., 2008). To date, only one research study has 
prospectively examined SHSe in medically at-risk children (i.e., pediatric cancer; (Tyc et 
al., 2013)), however no data exists examining SHSe in children of SCD using 
biological objective measurement. The three previous studies examining SHSe in SCD 
(Cohen et al., 2013; Glassberg et al., 2012; West et al., 2003) were retrospective (i.e., 
chart review) in design and included only self-report measurement regarding smoking 
status. Therefore, our approach is the first logical step to identifying the extent to which 
children who are diagnosed with sickle cell disease are exposed to SHSe. We only 
included primary caregivers with a child between the ages of 1 month-17-years-old, since 
this is the age range with the highest level of SHSe (Health & Services, 2006). We  chose 
the youngest child if the caregiver has more than one child whom he/she spends 4 or 
more hours with per day since previous research shows that younger children in this age 
range are typically exposed to higher levels of SHSe (Priest et al., 2008).  
 
Statistical Analyses: 
Sample Size 
 The focus of this proposal is not on statistical hypothesis testing, but rather on 
assessing preliminary prevalence rates of SHSe. Child salivary cotinine is the primary 
outcome of interest and thus we estimated power for the proposed study based on this 
outcome. For the current study, we enrolled 31 dyads. Four families declined to 
participate due to being too busy or not interested in participating in the study.  
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Data Analytic Plan Aim 1 
Aim 1: To determine the prevalence of secondhand smoke exposure in children 
diagnosed with SCD via self-report, parental report, and objective measurement (i.e., 
salivary cotinine).  
Hypothesis 1.1: Based on previous non-representative studies, it was expected 
that approximately 30 – 40% of sample would be exposed to SHSe, which would be 
consistent with the three studies in the literature to date. 
Aim 1 Analyses: The prevalence of SHSe was calculated as a measure of 
frequency (Ressing, Blettner, & Klug, 2010).  
 
Data Analytic Plan Aim 2:  
Aim 2: To examine the relationship between levels of salivary cotinine and 
utilization of health care services (i.e., Emergency Department Visits) and negative health 
events (e.g., acute chest syndrome, sickle cell crises, pulmonary morbidity).    
Hypothesis 2.1: Youth who have cotinine values > .15 ng/mL, an indication of 
significant SHSe (Salimetrics, 2014; Benowitz, et al., 2009), will demonstrate an increase 
in utilization of health care services (i.e., Emergency Department Visits) and negative 
health events (e.g., acute chest syndrome, sickle cell crises, pulmonary morbidity) 
compared to youth who have a cotinine values less than .15 ng/ml (Salimetrics, 2014; 
Benowitz, et al., 2009).  
Aim 2 Analyses: All cotinine values were examined using the Salimetrics 
(Salimetrics, 2014) research guidelines (Benowitz, Bernert, Caraballo, Holiday, & Wang, 
2009) to determine if caregivers are active tobacco/nicotine users and the level of SHSe 
for the child.  A person who is actively using tobacco/nicotine product will typically have 
cotinine values ≥3 ng/mL (Salimetrics, 2014; Benowitz, et al., 2009). Therefore, we  used 
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cotinine values > .15 ng/mL to indicate SHSe (Salimetrics, 2014; Benowitz, et al., 2009). 
We hypothesized that youth who have cotinine values greater than .15 ng/mL would 
demonstrate an increase in utilization of health care services (i.e., Emergency Department 
Visits) and increased maladaptive health events (e.g., acute chest syndrome, sickle cell 
crises, pulmonary morbidity) compared to youth who have a cotinine values less than .15 
ng/mL (Salimetrics, 2014; Benowitz, et al., 2009).  
Descriptive Statistics 
To provide additional information about caregiver nicotine/tobacco use and 
caregiver perceptions of relative harm related to specific tobacco/nicotine products 
descriptive statistics were utilized. Bivariate correlations were employed to examine any 
potential correlations between child or caregiver demographic information and child 
cotinine, child emergency department utilization, number of sickle cell crises, and 
number of acute chest syndrome. Caregivers were asked about current use of 
tobacco/nicotine (i.e., “Do you now smoke regular cigarettes”) and previous or ever-use 
of tobacco (i.e., “Have you smoked at least 100 regular cigarettes in your life?”, “Please 
select which answer best describes your experience with the following products: never 
tried, not even once, tried it before, use occasionally, or use daily.”, and “What was the 
first tobacco product you’ve ever tried?”).  
Caregivers were also asked about the number of the individuals in the home who 
use a tobacco or nicotine product to assess household SHSe or secondhand vape exposure 
(SHVe; “How many people in your home: smoke regularly cigarettes, use an e-cigarette, 
use a tank system, use both regular cigarettes and a e-cigarette/tank system.”). To assess 
caregiver perceptions of harm, two questions were utilized: 1) “Which, if any, of these 
products are safer than regular cigarettes?”; 2) “On a scale from 0 – 10, where 0 = not at 
all harmful, and 10 = extremely harmful, how harmful to your health do you think the 
following are?”.  Please see Appendix B for entire nicotine/tobacco questionnaire. 
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Missing Data: In the event of missing data, we contacted participants 
immediately by phone. However, if they refused to be contacted or otherwise lose contact 
with the investigators, we censored data at point of loss. When possible, we used a more 
conservative intent to treat approach in which missing outcomes are imputed using last 
observation carried forward (LOCF). 
 
Limitations and Pitfalls. The first anticipated problem is that children and parents 
may refuse to enroll in the study. Therefore, we  asked these individuals to provide 
reasons for non-participation to allow for feasibility and acceptability assessments for the 
proposed study. The second anticipated problem arises from our enrollment of youth 
across a large developmental range (e.g., 1 month-17-years-old). A broad developmental 
range was chosen over a more restricted one because the previous research has shown 
that children experience the highest amount of SHSe of all age groups, with more than 50% 
of children in the U.S. exposed to secondhand smoke (Control & Prevention, 2010; 
Health & Services, 2006). Children who are between the ages of 3 to 11-years-old have 
the highest levels of SHSe, likely because they spend a majority of their time in close 
proximity to a caregiver who smokes (Gergen et al., 1998; Health & Services, 2006; 
Pirkle et al., 2006; Schwab et al., 1992).  
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CHAPTER II 
 
FINDINGS 
 
Spirometry 
Due to the age of the child (Mage = 2.72; SD = 1.77), seven of the 31 children did not 
provide pulmonary functioning measurement. Overall, majority of children had spirometry results 
in the normal range (FEV1 between 80% and 120%, n = 19, 61.3%; FEV1/FCV greater than 70% 
predicted, n = 22, 71.0%). Of the 24 participants who completed forced spirometry, 11 were 
previously diagnosed with asthma, but the majority fell in the normal range of pulmonary 
functioning (FEV1 between 80% and 120%, n = 10, 90.9%; FEV1/FCV greater than 70% 
predicted, n = 6, 54.5%). All medical information and biochemical data are reported in Table 3 in 
Appendix C. 
 
Exhaled Carbon Monoxide 
Overall, the majority of families in the present study had nonsmoking estimates (eCO ≤ 
10 p.p.m.) of eCO (caregiver eCO M = 3.93 p.p.m.., SD = 4.54; child eCO M = 4.35, SD =2.58). 
eCO values are in Table 3, Appendix C. 
 
 
Salivary Cotinine 
 Due to equipment malfunction, four samples were unable to be processed. Of the 
remaining 27 samples, 24 children were exposed to SHS via ng/mL of .15 or greater (Mcotinine= .92, 
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SD = 1.28, Range = 0.00 ng/mL – 5.47 ng/mL). Cotinine values are reported in Table 3 in 
Appendix C.  
 
Data Analyses for Specific Aims 
Aim 1: To determine the prevalence of secondhand smoke exposure in children 
diagnosed with SCD via self-report, parental report, and objective measurement (i.e., 
salivary cotinine).  
Hypothesis 1: Based on previous non-representative studies, it was expected that 
approximately 30 – 40% of sample will be exposed to SHSe, which would be consistent 
with the three studies in the literature to date.  
Aim 1 Results: In the present study, the prevalence of SHSe was calculated as a 
measure of frequency (Ressing, Blettner, & Klug, 2010). According to exhaled CO and 
parental self-report, only six of the 31 children (19%) were exposed to secondhand smoke. 
However, when examining exposure related to levels of salivary cotinine, 24 of the 27 
participants (88%) had cotinine levels greater than .15 ng/mL (Mcotinine = .92, SD = 1.28). 
It should be noted that due to equipment malfunction four participants salivary samples 
were unable to be processed. Physician reported secondhand smoke exposure 
successfully identified two of the six biochemically confirmed and self-reported caregiver 
smokers. Of the remaining 29 participants, 21 were nonexposed/nonsmoking families via 
physician report, and no information regarding secondhand smoke exposure was 
provided for five families.  
 
 
Aim 2: To examine the relationship between levels of salivary cotinine and 
utilization of health care services (i.e., Emergency Department Visits) and negative health 
events (e.g., acute chest syndrome, sickle cell crises, pulmonary morbidity).    
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Hypothesis 2: Youth who have cotinine values greater than .15 ng/mL, will 
indicate significant SHSe (Salimetrics, 2014; Benowitz, et al., 2009), will demonstrate an 
increase in utilization of health care services (i.e., Emergency Department Visits) and 
negative health events (e.g., acute chest syndrome, sickle cell crises, pulmonary 
morbidity) compared to youth who have a cotinine values less than .15 ng/mL (i.e., no 
exposure; Salimetrics, 2014; Benowitz, et al., 2009).  
Aim 2 Analyses: All cotinine values were examined using the Salimetrics 
(Salimetrics, 2014) research guidelines (Benowitz, Bernert, Caraballo, Holiday, & Wang, 
2009) to determine if caregivers are active tobacco/nicotine users and the level of SHSe 
for the child.  A person who is actively using tobacco/nicotine product will typically have 
cotinine values ≥3 ng/mL (Salimetrics, 2014; Benowitz, et al., 2009).  
Aim 2 Results: In the present sample, 24 of the 27 children had cotinine values 
≥.15 ng/mL, of those children that were exposed. The majority of children had cotinine 
values less than 1 but greater than .15 ng/mL (n = 22; range = .21 ng/mL - .96 ng/mL). 
Two children had cotinine values between 1 ng/mL and 2.9 ng/mL (1.07 ng/mL; 2.75 
ng/mL). Two children had cotinine levels similar to that of a light smoker (e.g., ≥3 ng/mL; 
4.41 ng/mL and 5.47).  Nine caregivers endorsed nicotine/tobacco exposure in the home 
via self-report (n = 2 electronic cigarette, Mcotinine = .48 ng/mL, SD = .01 ng/mL); n = 7 
cigarette tobacco, Mcotinine =1.64 ng/mL, SD = 2.11 ng/mL). The mean difference in 
cotinine values for caregiver reported household exposure (Mcotinine = .1.36 ng/mL, SD 
= .1.87 ng/mL) versus no report of household exposure (Mcotinine = .63 ng/mL, SD = .38 
ng/mL) was .73 ng/mL. Because 24 of the 27 individuals were exposed to SHSe, no 
inferential statistical analyses could be conducted.  
 
Descriptive Statistics 
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No significant correlations were observed between child or caregiver demographic 
information and child cotinine, child emergency department utilization, number of sickle cell 
crises, and number of acute chest syndrome. However, caregiver endorsement of using 100 or 
more cigarettes in their lifetime and child cotinine was significantly correlated at the p≤ .05 level 
(r = .482). Number of sickle cell crises was significantly correlated with number of emergency 
department utilizations (r = .863) and number of acute chest syndrome (r = .730), both at the p≤ 
.001 level. Lastly, acute chest syndrome and the number of emergency department utilizations 
were significantly correlated at the p≤ .001 level (r = .686). All other correlations are reported in 
Table 4 in Appendix C.  
 Eight of the 31 caregivers reported smoking 100 cigarettes or more in their lifetime. 
Twenty-seven caregivers denied smoking cigarettes on a regular basis, two caregivers indicated 
using cigarettes daily, and two caregivers endorsed using cigarettes occasionally. No caregivers 
endorsed ever using dissolvable tobacco or snus, one caregiver had previously used roll your own 
cigarettes, and two caregivers endorsed previous hookah use. The majority of caregivers had 
never tried electronic cigarettes (n = 24), five caregivers had previously tried electronic cigarettes, 
one caregiver endorsed occasional electronic cigarette use, and one caregiver endorsed daily use.  
The majority of caregivers had never tried nicotine replacement therapy (NRT; n = 30) with one 
caregiver endorsing previous use.  
Perceptions of products safer than traditional tobacco cigarettes, four caregivers endorsed 
skoal, one caregiver endorsed snus, and one caregiver endorsed hookah as safer than traditional 
tobacco cigarettes. Interestingly, 11 caregivers perceived electronic cigarettes, and 9 caregivers 
perceived NRT as safer than traditional tobacco cigarettes. No caregivers thought dissolvable 
tobacco or roll your own cigarettes were safer than traditional tobacco cigarettes. All caregivers 
reported all nicotine and tobacco products, as well as NRT and smoking cessation medications 
(i.e., Wellbutrin, Chantix), as potentially harmful (Range M= 5.97 to M = 9.26). Additional 
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descriptive statistics related to nicotine/tobacco use and perceptions of harm/safety are reported in 
Table 5 in Appendix C.  
Caregivers were also asked to report their tobacco history starting with the first tobacco 
product ever tried. Ten caregivers reported traditional tobacco cigarettes as their first tobacco 
product tried, two caregivers reported beginning use with smokeless (e.g., skoal) tobacco, and one 
caregiver reported first use began with NRT. Two caregivers endorsed an electronic cigarettes as 
the first product used,  and two endorsed marijuana as the first product ever used.  Lastly, 
caregivers were asked to report “how many people in your home use the following products: 
Regular Cigarettes, Electronic Cigarettes, Tank Electronic Cigarette, and/or Both Regular 
Cigarettes and an Electronic Cigarette.”  Seven caregivers reported someone in their household 
used traditional cigarettes, one caregiver reported household use of an electronic cigarette, one 
caregiver indicated household use of a tank system, and no caregivers endorsed household use of 
both regular cigarettes and a tank or electronic cigarette system. Please see Table 5 in Appendix 
C for additional information related to caregiver nicotine/tobacco use. 
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CHAPTER V 
 
 
CONCLUSIONS 
The present study sought to achieve two aims, first to estimate the number of children 
diagnosed with sickle cell disease who are exposed to secondhand smoke (SHSe), and second, to 
assess if SHSe among children with sickle cell disease is associated with increased utilization of 
health care (i.e., emergency department utilization) services and increased disease severity (i.e.,  
higher frequency of sickle cell crises and/or acute chest syndrome, increased pulmonary 
morbidity). To assess the first objective, eCO and child cotinine, a biological marker of nicotine 
exposure, were utilized. The majority eCO were in the normal or nonsmoking range. According 
to eCO and parental self-report, only six of the 31 children (19%) were exposed to secondhand 
smoke. However, salivary cotinine indicated 24 of the 27 participants (88%) were exposed in 
some capacity to SHSe, with cotinine levels greater than .15 ng/mL.  
To assess the second objective, children completed spirometry to assess pulmonary 
functioning and medical information was collected through a medical chart review. Contrary to 
the hypothesized relationship of SHSe and health outcomes, no associations between SHSe and 
increased health care utilization, sickle cell disease morbidity, or estimates of pulmonary 
morbidity were observed. Additional information regarding caregiver nicotine/tobacco history 
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and perceptions of harm were examined using descriptive statistics. Eight caregivers reported 
smoking 100 cigarettes or more in their lifetime and the majority of caregivers had never tried 
electronic cigarettes (n = 24), or nicotine replacement therapy (NRT; n = 30).  Related to 
perceptions of harm, 11 caregivers perceived electronic cigarettes as safer than traditional tobacco 
cigarettes.  
Overall, the findings in this study partially support the findings in the three previous 
studies examining SHSe in youth with sickle cell disease (i.e., West et al., 2003, Glassberg et al, 
2012, Cohen et al., 2013), with several exceptions. First, West and colleagues (2013) found that 
self-, caregiver-, and physician-reported SHSe via questionnaire and medical chart review were 
indicative of increased medical utilization and pulmonary morbidity in youth with SHSe. 
However, in the present study, self-, caregiver-, and physician-reported SHSe were poor 
indicators of actual SHSe, with the majority of ratings indicating no exposure. This similar to 
other studies with a majority sample of African American (see Wilson, Kahn, Jhoury, & 
Lanphear, 2005), which report lower reported exposure to SHSe. Second, in the present study no 
correlations between SHSe (i.e., cotinine or eCO) and negative health outcomes/medical 
utilization were observed. Glassberg and colleagues (2012) identified that sickle cell crises and 
increased asthma morbidity related to SHSe significantly increased emergency department 
utilization and the frequency of the previously mentioned health outcomes. However, the present 
study found no correlations between SHSe, asthma morbidity, decreased pulmonary functioning, 
or sickle cell crises. Lastly, the findings of Cohen and colleagues (2013), which identified that 
44% of patients reported a history of SHSe, and 29% reported current SHSe, were again, not 
upheld in the present study. Only 22.58% of the current sample reported any SHSe, however 24 
of the 27 cotinine samples (88%) indicated SHSe. Cohen and colleagues (2013) also identified a 
relationship between SHSe and increased airway obstructive via spirometry. The findings in the 
present study only identified increased airway obstructive in 38% of children, regardless of SHSe 
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or a previous physician diagnosis of asthma.   
The present study highlights some important considerations. First, 24 of the 27 children 
in the present study were exposed to SHSe or secondhand vapor (SHVe) via salivary cotinine. 
Interestingly, seven caregivers endorsed household exposure via traditional tobacco cigarettes and 
two caregivers endorsed electronic cigarettes use (secondhand vapor; SHVe). Despite the 
relatively low levels of cotinine exposure (i.e., majority of cotinine values between .15 ng/mL and 
1 ng/mL), it is important to note that there is no safe level of SHSe/SHVe (United States Surgeon 
General Report, 2006; Wilson, Klein, Blumkin, Gottlieb, & Winickoff, 2011; Oono, Mackay, & 
Pell, 2011). According to the United States Surgeon General Report (2006),  nearly 22 million 
children (60%) in the United States aged 3 -11 cotinine to be exposed to SHSe. This exposure 
increases the rates of sudden infant death syndrome, acute respiratory infections, and increases 
asthma morbidity (United States Surgeon General Report, 2006), regardless of the level of SHSe. 
A recent study found even higher SHSe rates than the documented SHSe rates in the United 
States Surgeon General Report (2006). The National Health and Nutrition Examination Survey 
(NHANES; Wilson et al., 2011) found that 73% of children are exposed to SHSe. Wilson and 
colleagues (2011) also document that this exposure is not limited to caregiver smoking, but that 
house-type (e.g., apartment, duplex, and detached or single-family homes) may increase the 
amount of SHSe. Interestingly, Wilson and colleagues (2011), identified a stratified increase in 
SHSe via cotinine related to the type of housing, with children living in apartment complexes 
having greater increases in SHSe than children who lived in detached or single-family homes. In 
the present study, no information on housing-type was included, and the high prevalence of SHSe 
may be indicative of SHSe/SHVe due to seepage through a wall or through shared ventilation 
systems in an apartment or duplex.  
The high prevalence of SHSe in the present study may also be a result of the lax tobacco 
control policies within the state in which the study was conducted. Findings from the literature 
show that stronger policies or a greater coverage of state-level smoke-free policies are associated 
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with a lower prevalence of adult smoking (Eriksen & Cerak, 2008; International Agency for 
Research on Cancer, 2009; Dinno & Glantz, 2009). Dove et al. (2010) used cross-sectional data 
from NHANES and found that children from non-smoking homes living in counties with 
extensive coverage of smoke-free air laws had lower cotinine levels than similar children living in 
counties without smoke-free laws. Additionally, tobacco use trends in the United States indicate 
significant SHSe for children from lower socioeconomic and educational households (Hiscock, 
Bauld, Amox Fidler, & Munafo, 2012). Despite the decline of smoking uptake and SHSe 
throughout the United States, SHSe continues to remain a potential problem among lower 
socioeconomic and education households (Escobedo & Peddicord, 1997; Garfinkel, 1997). 
Notably, in the present study, a large portion of the caregivers in the present sample were high 
school graduates (45.20%), had government assisted (e.g., Medicaid/Medicare; 35.50%) or no 
insurance (9.7%), were single parents (51.70%), and made less than $30,000 (60.00%). 
Additionally, it should be noted that several studies have identified that African American have 
higher levels of cotinine (e.g., Benowitz et al., 1994, 2009; Perez-Stable et al., 1998, Knight et al., 
1996; Wilson, Kahn, Khoury, & Lanphear, 2005). It is unclear if these differences are due to type 
of tobacco products used (e.g., menthol cigarettes, cigarillos; Kabat et al., 1991) or differences in 
metabolizing tobacco/nicotine products (Benowitz et al., 1994, 2009; Perez-Stable et al., 1998).  
Despite the important findings of this study, the results are limited in generalizability due 
to the low sample size (n= 31) and the cross-sectional design. Additionally, the low sample size 
and the high prevalence of SHSe prevented the utilization of inferential statistics. However, the 
ability to increase this sample size was limited in that only four of the 35 caregiver approached 
declined. Despite these limitations, the present study has several advantages over previous studies 
in that it was employed in a regular clinic setting and it was the first study to obtain biochemical 
confirmation of SHSe (i.e., cotinine). This study also highlighted the benefit of salivary cotinine 
to measure SHSe as opposed to more traditional methods of determining SHSe (cotinine versus 
eCO). The findings in the present study show that SHSe may not be attributed to a primary 
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caregiver per se, but may be a result of household SHSe from a variety of other sources.  
Overall, the present study highlights the need for future studies to evaluate SHSe in youth 
with sickle cell disease. Based on the findings in the present study, SHSe appears to be a 
significant concern with 88% of the sample having detectible cotinine levels, which is only 
obtainable from tobacco/nicotine exposure, via salivary EIA analysis. Due to a lack of eCO and 
self-, parent-, and physician-reported SHSe, it is recommended that future studies utilize other 
forms of biochemical verification, such as salivary or serum cotinine, to assess for SHSe. Future 
studies utilizing a larger sample size and a longitudinal design are also needed to assess trends 
among health related outcomes such as pulmonary morbidity, increased emergency department 
utilizations, and sickle cell crises.  
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Chapter Overview 
  Sickle Cell Disease: Description and Disease Implications 
 
Nature and Etiology of Sickle Cell Disease 
In the United Statues, the exact number of people living with SCD is unknown (National 
Heart, Lung, and Blood Institute, 2009). However, the Center for Disease Control and Prevention 
(CDC), in collaboration with the National Institutes of Health (NIH) and 7 states (i.e., California, 
Florida, Georgia, North Carolina, New York, Michigan and Pennsylvania) have combined efforts 
to establish a prevalence rate of children and adults living with SCD. The CDC (2014) and NIH 
(2009) estimate that SCD affects 90,000 to 100,000 Americans, occurs among 1 out of every 500 
Black or African-American births, and in about 1 out of every 36,000 Hispanic-American births. 
It is estimated that sickle cell trait (SCT) occurs among about 1 in 12 Blacks or African 
Americans.  
SCD includes a collection of autosomal recessive genetic disorders involving the 
abnormal production of hemoglobin. In SCD, red blood cells are short-lived and brittle, assuming 
a “sickled” shape that hinders their ability to effectively deliver oxygen throughout the body 
(Barakat, Nicolaou, O’Hara, & Allen, 2009). In addition, impaired red blood cells often aggregate 
to occlude other smaller blood vessels and significantly reduce the amount of oxygenated blood 
to the lungs and other organs (Serjeant, 1997). Variants of the disease range in severity from the 
most severe, homozygous (HbSS), to heterozygous SCD, which is associated with benign 
symptoms (Barakat, Nicolaou, O’Hara, & Allen, 2009). Individuals who carry SCT generally do 
not experience symptoms associated with the disease (Rees et al., 2003). Due to the advancement 
of treatment and early neonatal testing, mortality rates associated with SCD and SCT have 
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declined significantly in the past twenty years (Platt et al., 1994), However, individuals diagnosed 
with SCD/SCT continue to have life expectancy rates below the general population (Platt et al., 
1994).  
Children and youth diagnosed with SCD face numerous chronic symptoms, ranging from 
stroke and pulmonary hypertension to more common side effects such as acute chest syndrome 
and acute pain associated with vaso-occlusive episodes, also known as sickle cell crises (CDC, 
2014). Acute chest syndrome, a leading cause of death marked by pulmonary infiltrate, fever and 
respiratory distress (Vichinsky et al., 2000), is a life-threatening complication of SCD that causes 
chest pain, fever and difficulty breathing and can be caused by a lung infection or by a sickle cell 
crisis. A sickle cell crisis occurs when the sickle cells block blood flow and decrease oxygen 
delivery to vital organs (NIH, 2015). Sickle cell crises can occur without warning and cause sharp 
and intense stabbing or throbbing pain throughout the body (NIH, 2015). A crisis can be a result 
of acute illness, extreme temperature changes, stress, and dehydration (NIH, 2015).  Often it is 
difficult to pinpoint the specific catalyst of a sickle cell crisis, but literature over the past decade 
has found that exposure to and use of tobacco may exacerbate and potentially increase the 
likelihood of having a sickle cell crisis (e.g., West et al., 2003).  
 Tobacco decreases oxygen flow to the lungs and can affect tissues throughout the body. It 
can cause lung infection and permanent lung damage, such as chronic obstructive pulmonary 
disease (COPD) and emphysema (Control & Prevention, 2013). In children and youth with SCD, 
short-term and long-term lung problems are more common such as pulmonary infection and 
asthma (NIH, 2015). In nonsmokers, the damaging effects of SHSe has on health is well 
documented (e.g., Helsing, Sandler, Comstok, & Chee, 1988; Albulhosn, Morray, Llewellyn, & 
Redding, 1997). For children and youth with sickle cell, exposure to tobacco smoke can cause 
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blood vessels to become smaller, which can lead to a pain crisis (West et al., 2003). An additional 
hazard of SHSe occurs when the nicotine in secondhand smoke attaches to hemoglobin, lowering 
the oxygen level in the blood, and subsequently triggering a sickle cell crisis (St. Jude Children’s 
Research Hospital, 2012). Despite the specific dangers to children and youth with SCD, little to 
no research has been conducted examining the specific impact secondhand smoke exposure 
(SHSe) has on health outcomes. More importantly, no studies, to our knowledge, have used 
objective measures to identify SHSe in a cross-sectional study sample. Therefore, understanding 
the specific impact SHSe has on children and youth with SCD is imperative. In the following 
sections, we will review the three primary studies that have been published to-date examining 
SHSe in SCD.  
Secondhand Smoke Exposure in Sickle Cell Disease 
Study 1: West et al., 2003 
 The purpose of the current study was to determine whether children and adolescents (n = 
52, MAge = 12.6 years; SD = 3.5 years) with SCD exposed to SHSe at home (n = 22; 42%) had 
more sickle cell crises than those who lived in nonsmoking households. A research assistant 
blinded to the participants’ family smoking history (smoker versus nonsmoker) retrospectively 
examined the medical record of each participant during the two years prior to participating in the 
study (1998-2000). Total hospital costs, length of stay, outpatient visits, fetal hemoglobin levels, 
and asthma or other pulmonary illnesses were calculated for each participant. SHSe was 
determined during a survey of the primary caretaker and the patient if the patient was 7 or older 
and a smoking household was determined if the primary caregiver or the patient identified anyone 
living in the home who smokes tobacco products either outside or inside the home during the two 
year prior to the study visit.  
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Using a Wilcoxon rank sum test to compare the number of sickle cell crises (including acute chest 
syndrome and stroke), the number of hospitalized days, total hospital cost, and total number of 
outpatient visits, West et al., (2003) found that children with SHSe had significantly more 
inpatient sickle cell crises (exposed: MAge = 3.7, SD = 5.7; nonexposed: MAge = 1.7, SD = 3.5; p = 
.02) and more hospitalized days (exposed: DaysM = 23.4, SD = 51.1; nonexposed: DaysM = 9.3, 
SD = 23.4, p = .48). No significant difference was observed between outpatient visits and total 
hospital costs. Using poisson regression, controlling for age and sickle cell type, SHSe were 
independently associated with more inpatient sickle cell crises and those patients diagnosed with 
homozygous S sickle cell anemia (West et al., 2003).  
The findings from West and colleagues (2003) provides a foundation linking the known 
biological and dose-dependent effects of SHSe as a potential mechanism for increasing the 
exacerbation of sickle cell crises in children/youth diagnosed with SCD. Overall, West et al. 
(2003), found that children and youth with SCD with SHSe were more likely to have acute sickle 
cell crises requiring hospitalization and greater hospital costs than those who were not exposed, 
suggesting that SHSe may influence the severity of SCD. In fact, West and colleagues (2003) 
found that patients with SHSe had 1.9 times the risk of a sickle cell crisis than did unexposed 
patients. The limitations for West et al. (2003) included obtaining SHSe via self- and patient-
report only and using retrospective chart review. The present study will address these limitations 
partly by imploring a more direct quantitative measure of SHSe (i.e., cotinine and NNAL 
measurement), which will determine whether the association of SHSe with inpatient sickle cell 
crises demonstrates a dose-response pattern.  
Study 2: Glassberg et al. (2012) 
 Glassberg and colleagues (2012) sought to examine clinical, social and environmental 
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factors that may increase emergency department intakes (ED) among children and youth with 
SCD. They examined ED visit between 2004 and 2010 associated with SCD ED pain and acute 
chest syndrome admissions in Canada, England, France and the United States. For the purpose of 
the present study, only the results for the United States will be discussed. T-tests, chi-square tests, 
and multivariable negative binomial regression models were used to examine mean 
differences/proportions and adjusted rate ratios for ED visits, with separate models for pain ED 
visits and acute chest ED visits (Glassberg et al., 2012). Covariates included age, sex, sickle cell 
genotype, asthma diagnosis (e.g., self-report verified via medication documentation in electronic 
medical chart), fetal hemoglobin percent and SHSe via in-home smokers.  Eight hundred and ten 
youth (MAge =8.71, AgeRange = 6.88-10.83; 51.4% male; 97.8% Black or African American; 70.5% 
on Medicaid; M = $20-29,999; 53.7% below poverty line) were included in the ED analyses for 
pain and acute chest syndrome admission (Glassberg et al., 2012).  
Overall, a previous diagnosis of asthma was associated with a 28% increase in the 
frequency of ED visits for pain (rate ration [RR] = 1.28; 95% confidence interval [CI] = 1.04-
1.58, p = .02). Using a multivariable model, income below the deferral poverty line was 
associated with a 31% increase in ED visits for pain (RR = 131, 95% CI = 1.04-1.64, p = .02). 
Similar to the findings of West et al. (2003), the two variables associated with increased risk of 
ED visits for acute chest syndrome were asthma and SHSe (Glassberg et al., 2012). Exposure to 
SHSe within the home was associated with a 73% increase in the rate of ED utilization for acute 
chest syndrome (RR = 1.73, 95% CI= 1.09-2.74, p = .02) and a physician diagnosis of asthma 
was associated with a 60% increase in ED visits for acute chest syndrome (RR = 1.60, 95% CI = 
1.03-2.49, p = .04).  
 While SHSe was associated with a greater increase in the occurrence of acute chest 
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syndrome, asthma was the only variable associated with increased ED utilization for both pain 
and acute chest syndrome. More specifically, the presence of a household tobacco smoker was 
associated with a 73% increase in acute chest syndrome events when compared to those that did 
not have a household exposure. Thus, there are strong data regarding the association between 
SHSe and increase asthma morbidity (e.g., Chilmonczyk, et al., 1993; Strachan & Cook, 1998), 
and there are emerging data about its association with SCD morbidity (West et al., 2003; Cohen, 
DeBaun, Blinder, Strunk, & Field, 2010). These data strengthen the evidence that SHSe is 
associated with SCD morbidity, particularly lung disease. The limitations of Glassberg and 
colleagues (2012) include retrospective report regarding past SHSe via patient and self-report 
only. The present study improves on these findings partly by using quantitative measures of SHSe 
(i.e., cotinine and NNAL measurement), which will determine whether the association of SHSe 
with acute chest syndrome ED visits demonstrates a dose-response pattern.  
 Study 3: Cohen et al. (2013) 
 Cohen et al. (2013) employed a cross-sectional analysis of 252 children, ages 4 to 20-
years-old (n = 126, MAge = 11, AgeRange = 4-18, 52% male), with asthma and sickle cell anemia 
(SCA) to examine spirometry, specifically airway obstruction, bronchodilator responsiveness and 
SHSe from three sites, including Missouri, Ohio, and London, England. Parents of children with 
SCA were asked questions about past and present in-home SHSe. Using logistic regression 
models to examine associations between SHSe and airway obstruction and bronchodilator 
responsiveness, Cohen and colleagues (2013) found that roughly 108 of the 245 children (44%) 
self-reported a history of exposure to SHSe and 71 of the 245 (29%) reported current exposure to 
SHS. Additionally, results of the logistic regression found that of those children with SHSe, SHSe 
during infancy and preschool periods were associated with poorer spirometry results. More 
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specifically, these children had poorer forced expiratory flow (i.e., the speed of air coming out of 
the lungs during the middle portion of a forced expiration), decreased midexpiratory phase/FVC 
ratio (i.e., the ratio of speed of air and force of air coming from the lungs), and increased airway 
obstruction and increased bronchodilator responsiveness (i.e., a phenotypic characteristic of 
chronic obstructive pulmonary disease; Cohen et al., 2013). Further, the FEV1/FVC value was 
below the lower limit of normal observed levels in healthy black children, with more reports of 
daytime cough/wheezing during physical activity, and nighttime cough/wheezing causing 
awakening (Cohen et al., 2013). Overall, Cohen et al. (2013) demonstrates that early SHSe is 
associated with airway obstruction in children with SCA. Similar to Glassberg et al. (2012) and 
West et al. (2012), limitations of this study included utilization of caregiver- and self-report only 
of SHSe.  
 The Current Study  
To address the limitations and to expand on the findings of West et al. (2003), Cohen et al. 
(2013), and Glassberg et al. (2012) the present study aimed to be the first to objectively measure 
SHSe via salivary cotinine, establish prevalence of SHSe in youth with SCD/SCA and 
preliminarily investigate the likelihood of a dose-response relationship between salivary cotinine 
and negative health events (i.e., increased ED use, increased occurrence of sickle cell crises and 
acute chest syndrome). Thirty-one caregiver-child dyads were recruited during a regularly 
scheduled clinic visit. Children will provided a saliva sample, completed a measure of lung 
functioning (i.e., spirometry) and exhaled carbon monoxide test. Self-report measures asked 
caregivers about their history of nicotine use Information regarding number of clinic visits, health 
care utilization and illness characteristics will be collected via electronic medical chart review.  
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Specific Aims 
Aim 1: Identify any differences in health care of children diagnosed with sickle cell in families 
who smoke versus those who are nonsmokers.  
Aim 2: To identify any physical effects of secondhand smoke on kids with sickle cell (i.e., 
spirometry and salivary cotinine) compared to children who are not exposed to secondhand 
smoke.  
Chapter Summary 
Despite public smoking bans, and the knowledge regarding the dangers of SHSe, this 
continues to be a significant problem of children and youth with caregivers that use tobacco 
products. Due to the limited research to date and the lack of cross-sectional and objective 
measurements, the present study aimed to address a significant gap in the current literature. A 
first-step is needed to understand 1) the prevalence of SHSe in SCD; 2) the impact SHSe may 
have on important health outcomes such as sickle cell crises, ED visits, and pulmonary 
functioning, and 3) insight into the level of salivary cotinine in youth/children with SCD. The 
present study aimed to address these questions and provide support for future investigations 
examining SHSe in SCD.  
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Demographics 
 
Child Sex:    F     M  Child Age:_______________  Child Date of 
Birth:_______________ 
Person Completing Form (relationship to child): ________________ 
Parent Sex:  F     M  Parent Age:______________   Parent Date of 
Birth:______________ 
Address: ____________________________________ 
Phone number: _______________________________ 
 
Ethnicity of Child:  ____ Caucasian  ____ Latino/Latina 
   ____ African American ____ Chicano/Chinana 
   ____ Asian   ____ Middle Eastern 
   ____ Pacific Islander  ____ American Indian 
   ____ Other (Please specify: _____________________________) 
Child’s Place of Birth: ______________  Child’s Primary Language: __________________ 
Mother’s Age:____________    Father’s Age:___________ 
Mother’s Education:     Father’s Education: 
 ____ High school graduate    ____ High school graduate 
 ____ College graduate    ____ College graduate 
 ____ Masters degree     ____ Masters degree 
 ____ PhD, JD, MD     ____ PhD, JD, MD 
 ____ other      ____ other 
 (please specify:___________________)  (please specify:___________________) 
Ethnicity of Mother:  ____ Caucasian  ____ Latino/Latina 
   ____ African American ____ Chicano/Chinana 
   ____ Asian   ____ Middle Eastern 
   ____ Pacific Islander  ____ American Indian 
   ____ Other (Please specify:_____________________________) 
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Ethnicity of Father:  ____ Caucasian  ____ Latino/Latina 
   ____ African American ____ Chicano/Chinana 
   ____ Asian   ____ Middle Eastern 
   ____ Pacific Islander  ____ American Indian 
   ____ Other (Please specify:_____________________________) 
Mother’s occupation:_____________________________________________ 
Father’s occupation:_____________________________________________ 
Approximate family income: 
 ____ < $10,000  ____ $41,000-50,000 
 ____ $10,000-20,000  ____ $51,000-60,000 
 ____ $21,000-30,000  ____ > $60,000 
 ____ $31,000-40,000 
Parent’s Marital Status:  ____ married     ____ separated     ____ divorced    
  ____ mother passed away     ____ father passed away     ____never married 
Are you CURRENTLY covered by any of the following types of health insurance or health 
coverage plans? 
1. Insurance through a current or former employer or union      
2. Insurance from an insurance company    
3. Medicare, for people 65 and older, or people with certain disabilities    
4. SoonerCare (Medicaid), Medical Assistance, Insure Oklahoma, or any other kind 
of government assistance plan for those with low incomes or disability 
5. Indian Health Service 
6. Any other type of health insurance or health coverage plan. Specify: _____ 
7. No health insurance 
-777. DON’T KNOW/NOT SURE  
-999. REFUSED  
-888.   N/A 
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Is your CURRENT residence in a rural (e.g., a geographic area that is located OUTSIDE cities 
and towns) or urban (e.g., a geographic area located INSIDE cities and towns) area? 
1. YES (rural)      
0. NO   (urban) 
 
-777. DON’T KNOW/NOT SURE  
-999. REFUSED  
-888.   N/A 
 
Was your PREVIOUS residence in a rural (e.g., a geographic area that is located OUTSIDE cities 
and towns) or urban (e.g., a geographic area located INSIDE cities and towns) area? 
1. YES  (rural)     
0. NO    (urban) 
 
-777. DON’T KNOW/NOT SURE  
-999. REFUSED  
-888.   N/A 
 
How long is your commute to your primary care physicians’ office? 
____________ Hours ___________ Minutes       
 
-777. DON’T KNOW/NOT SURE  
-999. REFUSED  
-888.   N/A 
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Nicotine and Tobacco Questionnaire 
1. Have you smoked at least 100 regular cigarettes in your lifetime?   
1. Yes  
2. No 
2. Do you now smoke regular cigarettes? 
1.  yes, everyday 
2.  yes, some days 
5.  Not at all 
3. Please select which answer best describe your experience with the following products? 
A. Smokeless chewing tobacco (e.g., Skoal, Copenhagen) 
1. Never tried, not even once 
2. Tried it before 
3. Use occasionally  
4. Use daily 
B. Dissolvable tobacco (Ariva, Stonewall, Camel Orbs, Camel sticks or strips) 
1. Never tried, not even once 
2. Tried it before 
3. Use occasionally  
4. Use daily 
C. Snus (Marlboro Snus, Camel Snus) 
1. Never tried, not even once 
2. Tried it before 
3. Use occasionally  
4. Use daily 
D. Roll-your-own cigarettes  
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1. Never tried, not even once 
2. Tried it before 
3. Use occasionally  
4. Use daily 
E. Smoking tobacco from a hookah or waterpipe  
1. Never tried, not even once 
2. Tried it before 
3. Use occasionally  
4. Use daily 
F. Electronic cigarettes or e-cigarettes (e.g., BluCig, SmokeTip, ProSmoke, 
NJoy) 
1. Never tried, not even once 
2. Tried it before 
3. Use occasionally  
4. Use daily 
G. Nicotine replacement products (e.g., nicotine gum, patch, lozenge, or 
inhaler) 
1. Never tried, not even once 
2. Tried it before 
3. Use occasionally  
4. Use daily 
H. Regular tobacco cigarettes (e.g., Marlboro, Camel, Winston, Newport) 
1. Never tried, not even once 
2. Tried it before 
3. Use occasionally  
4. Use daily 
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4.   Which if any of these products are safer than regular cigarettes? Select all that apply. 
1.  Smokeless, chewing tobacco (e.g., Skoal, Copenhagen) 
2.  Dissolvable tobacco (Ariva, Stonewall, Camel Orbs, Camel sticks or strips) 
3.  Snus (Marlboro Snus, Camel Snus) 
4.  Roll-your-own cigarettes 
5.  Smoking tobacco from a hookah or waterpipe 
6.  Electronic cigarettes or e-cigarettes 
7.  Nicotine replacement products (nicotine gum, patch, lozenge, inhaler) 
5.   What was the first tobacco product you ever tried? 
1.  I’ve never tried any tobacco product, not even once.  
2.  Regular tobacco cigarettes (e.g., Marlboro, Winston, Kool, Camel, etc.) 
3.  Smokeless, chewing tobacco (e.g., Skoal, Copenhagen) 
4.  Dissolvable tobacco (Ariva, Stonewall, Camel Orbs, Camel sticks or strips) 
5.  Snus (Marlboro Snus, Camel Snus) 
6.  Roll-your-own cigarettes 
7.  Smoking tobacco from a hookah or waterpipe 
8.  Electronic cigarettes or e-cigarettes 
9.  Nicotine replacement products (nicotine gum, patch, lozenge, inhaler) 
6. How many people in your home… 
 a. Smoke regular cigarettes  _______ 
  b. Use an e-cigarette   _______ 
 c. Use a tank system  _______ 
 d. Use both regular cigarettes and  
an e-cigarette/tank system  _______ 
7. On a scale from 0-10, where 0=”not at all harmful”, and 10=”extremely harmful”, how 
harmful to your health do you think the following are? 
         Product     Harm Rating 
Electronic 
Cigarettes 
 
Tank System  
Regular Cigarettes  
Smokeless Tobacco  
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Nicotine Gum  
Nicotine Patch  
Nicotine Lozenge  
Nicotine inhalator  
Chantix  
Wellburtin/Zyban  
Marijuana  
Hookah  
Snus  
 
 
8. On a scale of 1 – meaning not at all important and 10 – meaning extremely 
important, how important do you feel it is to quit using nicotine products_______? 
 
9. On a scale of 1 – meaning not at all confident and 10 – meaning extremely confident, 
how confident are you that you could quit using nicotine products_______? 
 
10. Please list the order in which you have tried the following products (write 0 or leave 
blank if you have never tried a product): 
         Product     Rank Order 
Electronic 
Cigarettes 
 
Tank System  
Regular Cigarettes  
Smokeless Tobacco  
Nicotine Gum  
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Nicotine Patch  
Nicotine Lozenge  
Nicotine inhalator  
Chantix  
Wellburtin/Zyban  
Marijuana  
Hookah  
Snus  
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Table 1. Caregiver Demographics  
Variable  Percent 
Age (years; M (SD))  37.58 (8.54) 
Relationship to Child  
     Father 12.9% 
     Mother 87.10% 
Ethnicity  
     African American 90.30% 
     White 3.20% 
     Middle Eastern 6.5% 
Annual Family Income  
     0 – 20,000 33.30% 
     21,000 – 40,000 33.40% 
     41,000 – 50,000  16.70% 
     60,000 or Greater 16.70% 
Education Level  
     High school graduate 45.20% 
     College graduate 32.30% 
     Master level graduate 6.50% 
     Undisclosed 16.10% 
Martial Status  
     Married 46.70% 
     Separated 10.00% 
     Divorced 6.70% 
     Never Married 36.70% 
Primary Insurance  
     Private 7.40% 
     Employer Provided 33.30% 
     Medicare 7.40% 
     SoonerCare or Medicaid 40.70% 
     No Insurance 11.10% 
Note. Percent of participants reported, unless otherwise noted.  
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Table 2.  Child Demographics.  
Variable Percent 
Age (years; M (SD)) 9.00 (4.48) 
Gender  
     Male 41.90% 
     Female 58.10% 
Ethnicity  
     African American 90.3% 
     White 3.20% 
     Middle Eastern 6.50% 
Sickle Cell Type  
     SS 45.20% 
     SC 41.90% 
     S/Beta 0 3.20% 
     HgbS/HgbD 3.20% 
     HgbS/Beta+Thalassemia 3.20% 
     Unspecified 3.20% 
Note. Percent of participants reported, unless otherwise noted.  
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Table 3. Medical Information and Biochemical Data 
 Variables  M (SD)  
Caregiver Exhaled CO 3.93 p.p.m. (4.54 p.p.m.) 
Child Exhaled CO 4.35 p.p.m. (2.68 p.p.m.) 
Child Previous Diagnosis of Asthma  
(Percent diagnosed) 
35.50% 
Child Cotinine .92 ng/mL (1.28 ng/mL) 
Number of Emergency Department Visits  
     30 days .32 (.65) 
     365 days 1.52 (2.47) 
Number of Sickle Cell Crises  
     30 days .19 (.48) 
     365 days 1.0 (2.05) 
Number of Acute Chest Syndrome 
Occurrences 
 
     30 days .06 (.25) 
Note. CO = Carbon Monoxide; p.p.m. = parts per million; ng/mL = Nanogram/milliliter; means 
(standard deviation), unless otherwise noted.  
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Table 4. Correlations 
 
Variables 1 2 3 4 5 6 7 8 9 10 11 
Child Gender 1 --- --- --- --- --- --- --- --- --- --- 
Child Age .312 1 --- --- --- --- --- --- --- --- --- 
Child 
Cotinine 
-.072 -.301 1 --- --- --- --- --- --- --- --- 
Caregiver 
Gender 
.063 .000 .045 1 --- --- --- --- --- --- --- 
Caregiver Age .020 .487** -.166 -.420* 1 --- --- --- --- --- --- 
SC Type -.313 -.001 .078 -.042 -.025 1 --- --- --- --- --- 
PAD -.190 .351 -.162 -.117 .181 -.147 1 --- --- --- --- 
EDV .325 .058 -.028 -.106 .097 -.200 .257 1 --- --- --- 
ACS  .223 -.295 -.114 .101 -.112 -.193 .080 .686** 1 --- --- 
SCC  .350 -.139 .094 -.046 -.037 -.187 .125 .863** .730** 1 --- 
Former/ 
Current 
Smoker 
.202 .184 .482* -.213 .284 -.060 .179 .048 -.155 .071 1 
Note. **= Correlation is significant at the 0.01 level (2-tailed). *=Correlation is significant at the 0.05 level (2-tailed). SC = 
Sickle Cell. EDV = Emergency department visits. ACS = Acute Chest Syndrome. SCC = Sickle Cell Crises. PAD = Previous 
Asthma Diagnosis. EDV, ACS, and SCC were documented in the medical record within 30 days of participation date. 
Former/Current Smokers were defined as those who endorsed having 100+ cigarettes in their lifetime.  
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Table 5. Caregiver-Reported Nicotine and Tobacco Use/Perceptions 
Variables  Frequency (Percent) 
More than 100+ Cigarette in Caregiver’s Lifetime  
     No 23 (74.20%) 
Current Regular Smoker   
    No 27 (87.10%) 
    Occasionally 2 (6.50%) 
Ever Tried (Yes)  
     Snus  1 (3.20%) 
     Hookah 2 (6.50%) 
    Electronic Cigarettes 7 (22.50%) 
     Nicotine Replacement Therapy 1 (3.20%) 
     Regular Cigarettes 6 (19.40%) 
Safer Than Regular Cigarettes (Yes)  
     Skoal 4 (12.90%) 
     Dissolvable Tobacco 0 
     Snus 1 (3.20%) 
     Roll Your Own Cigarettes 0 
     Hookah 1 (3.20%) 
     Electronic Cigarettes 11 (35.50%) 
     Nicotine Replacement Therapy 9 (29.00%) 
First Tobacco Product Tried   
     Regular Tobacco Cigarettes 13 (41.90%) 
     Smokeless Tobacco 2 (6.50%) 
     Nicotine Replacement Therapy 1 (3.20%) 
     Never Tried Tobacco 15 (48.40%) 
Number of People Who Use Tobacco/Nicotine  
    Regular Cigarettes 7 (22.60%) 
     Electronic Cigarettes 1 (3.20%) 
     Tank Electronic Cigarette 3 (9.70%) 
     Regular Cigarettes and Electronic Cigarettes 0 
Perception of Relative Harm (Mean (SD))   
     Electronic Cigarettes 6.42 (4.26%) 
     Tank Electronic Cigarette 7.33 (3.94%) 
     Regular Cigarettes 9.26 (2.50%) 
     Skoal 8.23 (3.43%) 
     Nicotine Gum 6.23 (4.33%) 
     Nicotine Patch 5.97 (4.29%) 
     Nicotine Lozenge 5.97 (4.35%) 
     Nicotine Inhalator 6.35 (4.30%) 
     Chantix 6.77 (4.07%) 
     Wellbutrin 7.20 (3.86%) 
	60	
     Marijuana 7.81 (3.51%) 
     Hookah 8.17 (3.20%) 
     Snus 8.29 (3.33%) 
Note. Perception of Relative Harm was ranked on a scale from 0 (not at all) to 10 (extremely).  
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